Profil
Mel L.
Billingsley is currently the President & Chief Executive Officer at Life Sciences Greenhouse of Central Pennsylvania since 2002.
He is also a Professor at The Pennsylvania State University.
He completed his undergraduate degree from the University of Pittsburgh in 1974 and received his doctorate degree from George Washington University.
Aktiva positioner av Mel L. Billingsley
| Företag | Position | Start |
|---|---|---|
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Verkställande Direktör | 2002-01-01 |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Företagsledare/Principal | - |
Mel L. Billingsleys utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 4 |
|---|---|
University of Pittsburgh
University of Pittsburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Pennsylvania State University
The Pennsylvania State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Life Sciences Greenhouse of Central Pennsylvania
Life Sciences Greenhouse of Central Pennsylvania Investment ManagersFinance LSGPA invests in companies located in the United States. The firm focuses on drug design, drug delivery systems, biomedical devices, biopharmaceutical manufacturing innovation, drug assay/detection/screening systems and bio nanotechnology. It participates in early-stage capital transactions. | Finance |
















